Printer Friendly

Sankyo Announces Completion of Subject Registration for ORIENT Clinical Trial.

Tokyo, Japan, Oct 15, 2005 - (JCNN) - Daiichi Sankyo announced on October 12 that its subsidiary Sankyo has completed the registration of subjects for ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial as of the end of September.

The ORIENT is a double-blinded study to examine the effectiveness of olmesartan medoxomil on patients with mild to moderate diabetic nephropathy. The study, which was launched in the second quarter of 2003 and ends in 2009, covers 400 patients in Japan and Hong Kong.

Currently, olmesartan medoxomil is an angiotensin II receptor blocker approved in 32 countries worldwide and marketed in Japan under the trade name of Olmetec.

Source: JCN

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:Oct 15, 2005
Previous Article:Medinet to Support University of Tokyo Hospital's 22nd Century Medical Center Project for Immune Cell Therapy.
Next Article:Meiji Seika Kaisha, Solvay Seiyaku Obtain Additional Approval for Fluvoxamine Maleate.

Related Articles
Major medical journals will require that randomized trials be registered.
Companies still hiding drug trial data, medical journals say.
Sankyo Licenses Cardiovascular Disease Drug Candidate KAI-9803 from KAI Pharmaceuticals.
Daiichi Sankyo Now Authorized to Market Its Products in China.
Clinical trials: the case for registration.
Ajinomoto, Sankyo in Joint Development, Manufacture and Marketing of AJD101, New Diabetes Drug.
Daiichi Sankyo Subsidiary Applies for Additional Indication for Fentanyl Injection.
Daiichi Sankyo Announces Completion of Phase I Trial on the Anti-influenza Drug CS-8958.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |